NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Insights - Lung Cancer Screening, Version 1.2022
The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.
Category
  • Lung Cancers
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Insights - Bladder Cancer, Version 2.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle-invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Category
  • Bladder Cancer
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Insights - Ovarian Cancer, Version 3.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
Category
  • Ovarian Cancer
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Insights - Survivorship, Version 1.2022
This article summarizes updates to the NCCN Guidelines pertaining to preventive health for cancer survivors, including recommendations about alcohol consumption and vaccinations.
Category
  • Survivorship
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
NCCN Guidelines® Insights - Gastrointestinal Stromal Tumors, Version 2.2022
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes.
Category
  • Soft Tissue Sarcomas
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Insights - Prostate Cancer, Version 1.2023
These NCCN Guidelines Insights summarizes much of the panel’s discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
Category
  • Prostate Cancer
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Well-Differentiated Grade 3 Neuroendocrine Tumors
It is important to inform clinicians about this new section of the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, which include recommendations for the evaluation, management, and surveillance of well-differentiated G3 NETs. Keeping clinicians abreast of updated treatment options may help improve clinical decision-making to better address patients’ medical needs.
Category
  • Neuroendocrine Tumors
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 CCM clock hours
  • 0.75 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Management of Unresectable or Metastatic Cutaneous Melanoma
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and will benefit from a comprehensive review of the novel treatments for cutaneous melanoma.
Category
  • Melanoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Non-Metastatic Prostate Cancer
Clinicians need to be knowledgeable about newer tools that can improve risk stratification, and they need to understand when these tools have the possibility to change management so that unnecessary testing can be avoided. In addition, clinicians should be educated about the heterogeneity among risk groups, so that nuanced discussions with patients can inform decisions surrounding active surveillance.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Pages